Brief: Lantern Pharma Announces Formation Of Starlight Therapeutics To Advance Transformative Therapies For Central Nervous System and Brain Cancers
06/03/2023 13:13
March 6 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FORMATION OF STARLIGHT
THERAPEUTICS TO
ADVANCE TRANSFORMATIVE THERAPIES FOR CNS (CENTRAL NERVOUS
SYSTEM) AND BRAIN CANCERS
* LANTERN PHARMA INC - CLINICAL TRIALS IN ADULT AND
PEDIATRIC CNS
CANCER INDICATIONS ARE ANTICIPATED FOR LATE 2023 AND EARLY 2024.
Source text for Eikon: ID:nBw9PZmCVa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments